Lifeboat Foundation

They reveal the origin of wine, the age of bones and fossils, and they serve as diagnostic tools in medicine. Isotopes and isotopologues—molecules that differ only in the composition of their isotopes—also play an increasingly important role in astronomy. For example, the ratio of carbon-12 (12C) to carbon-13 (13C) isotopes in the atmosphere of an exoplanet allows scientists to infer the distance at which the exoplanet orbits its central star.

Until now, 12C and 13C bound in carbon monoxide were the only isotopologues that could be measured in the atmosphere of an exoplanet. Now a team of researchers has succeeded in detecting ammonia isotopologues in the atmosphere of a cold brown dwarf.

As the team has just reported in the journal Nature, ammonia could be measured in the form of 14NH3 and 15NH3. Astrophysicists Polychronis Patapis and Adrian Glauser, who are members of the Department of Physics as well as of the National Centre of Competence in Research (NCCR) PlanetS, were involved in the study—Patapis as one of the first authors.

There were mixed reactions across gene editing space on Thursday after CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX), in a world’s first, won U.K. approval for their CRISPR-based drug exa-cel for sickle cell disease and beta-thalassemia.

CRISPR Therapeutics (CRSP) has added ~5%, and MaxCyte (NASDAQ: MXCT), which has a licensing deal with the Swiss biotech, has gained ~4%. Vertex Pharma (VRTX) is trading lower for the third straight session.

Other CRSPR-based drug developers Graphite Bio (GRPH) and Precision BioSciences (DTIL) are also among the gainers, while notable gene editing biotechs Editas Medicine (EDIT), Beam Therapeutics (BEAM), Intellia Therapeutics (NTLA), and Verve Therapeutics (VRTX) are in the red.

Major work led by Dr. André Veillette’s team at the Institut de recherches cliniques de Montréal (IRCM), in collaboration with a group of researchers, and just published in Nature Immunology, managed to identify a previously unknown molecular action that prevents phagocytosis, which is a process that promotes the immune system’s response to cancer. A Research Briefing on the work done by the team has been published in the same journal.

Macrophages are cells of the immune system. One of the roles of macrophages is to engulf, or “eat,” cells that are defective or dangerous, including cancer cells. This process is named phagocytosis. Macrophages can be called into action to eliminate cancer cells. However, this capacity is often defective, because macrophages are put in a state of dormancy by the cancer cells.

This is in part because a particular molecule called CD47 is often over-abundant on cancer cells. CD47 prevents phagocytosis by triggering a molecule or “receptor” on macrophages named SIRPα. Agents that block the ability of CD47 to trigger SIRPα have shown promising results for treating cancer.

The researchers used human stem cells to create a model of early brain development — organoids.

Super-resolution image of human stem cell-derived Microglia cells with labeled mitochondria (yellow), nucleus (magenta), and actin filaments (cyan). These Microglia cells help in the maturation of neurons in human brain organoid models. Photo credit: A*STAR’s SIgN

An international team of scientists has uncovered the vital role of microglia, the immune cells in the brain that acts as its dedicated defense team, in early human brain development.

Continue reading “New study reveals the critical role of microglia in human brain development” »

LONDON (AP) — Britain’s medicines regulator has authorized the world’s first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in the U.K. In a statement Thursday, the Medicines and Healthcare Regulatory Agency said it approved Casgevy, the first medicine licensed using the gene editing tool CRISPR, which won its makers a Nobel prize in 2020. The agency approved…

In a world first, regulators in the U.K. approved Crispr’s gene-editing treatment for two blood diseases on Thursday, and CRSP stock surged.

The devices demonstrated clinical-grade accuracy and introduced novel functionalities not seen in prior research or clinical care.

Northwestern University.

Furthering the scope of such examinations, a team of researchers at Northwestern University (NU) is now presenting novel wearable technology much more advanced than the intermittent measures made during periodic medical examinations.

Continue reading “Wearable device harnesses body sounds for continuous health monitoring” »

Cerebral small vessel disease is a significant cause of aging-related mental decline and accounts for almost half of all dementia cases globally.

Sudok1/iStock.

The research, published in the journal Stem Cell Reports, also suggests a possible drug target to prevent or treat the condition known as cerebral small vessel disease (SVD).

Continue reading “Cambridge team grows blood vessels to investigate brain diseases” »

Findings lay the groundwork for developing targeted therapies aimed at regulating epigenetic factors in cancer therapy.